
Jillian R Gunther

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/348278/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Assessment of Lymphoma and Other Hematologic Malignancies Training Needs Among Radiation Oncology Residents: a Brief Report. Journal of Cancer Education, 2023, 38, 201-205.	0.6	2
2	Implementation and Assessment of an Informal Virtual Elective for Medical Student Radiation Oncology Exploration During the COVID19 Pandemic: a Brief Report. Journal of Cancer Education, 2023, 38, 344-348.	0.6	1
3	Radiation Oncology Education Collaborative Study Group Annual Spring Symposium: Initial Impact and Feedback. Journal of Cancer Education, 2022, 37, 1504-1509.	0.6	1
4	Analyzing the Role of Research in the Radiation Oncology Match. Advances in Radiation Oncology, 2022, 7, 100891.	0.6	10
5	Outcome of relapsed and refractory nodular lymphocyteâ€predominant Hodgkin lymphoma: a North American analysis. British Journal of Haematology, 2021, 192, 560-567.	1.2	9
6	Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. Frontiers in Oncology, 2021, 11, 648655.	1.3	19
7	The Radiation Oncology Education Collaborative Study Group 2020 Spring Symposium: Is Virtual the New Reality?. International Journal of Radiation Oncology Biology Physics, 2021, 110, 315-321.	0.4	11
8	Identification of Blood-Based Biomarkers for the Prediction of the Response to Neoadjuvant Chemoradiation in Rectal Cancer. Cancers, 2021, 13, 3642.	1.7	6
9	The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leukemia and Lymphoma, 2021, 62, 1361-1369.	0.6	4
10	Long Term Outcome Patterns and Risk Factors for Early Mortality and Disease Progression in ALK-Positive Anaplastic Large Cell Lymphoma. Blood, 2021, 138, 2463-2463.	0.6	0
11	Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series. Blood, 2021, 138, 4536-4536.	0.6	0
12	Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma. Blood, 2021, 138, 3526-3526.	0.6	0
13	Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series. Blood, 2021, 138, 1448-1448.	0.6	0
14	Radiomic Phenotypes of High and Low Lesion SUV Components for the Prediction of Refractory Disease in Hodgkin's Lymphoma Patients Treated with ABVD Based Therapy. Blood, 2021, 138, 3996-3996.	0.6	0
15	Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. Leukemia and Lymphoma, 2020, 61, 171-175.	0.6	14
16	An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement. Cancer Medicine, 2020, 9, 663-670.	1.3	17
17	Decreased heart dose with deep inspiration breath hold for the treatment of gastric lymphoma with IMRT. Clinical and Translational Radiation Oncology, 2020, 24, 79-82.	0.9	10
18	Involved-Site Radiation Therapy if Minimal Toxicity. International Journal of Radiation Oncology Biology Physics, 2020, 107, 20-21.	0.4	0

#	Article	IF	CITATIONS
19	ILROG Lymphoma Mini-Atlas Part II, Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2020, 108, 977-978.	0.4	1
20	A Not So Perfect Score: Factors Associated with the Rate of Straight Line Scoring in Oncology Training Programs. Journal of Cancer Education, 2020, , 1.	0.6	1
21	Effect of Deep Inspiration Breath Hold on Normal Tissue Sparing With Intensity Modulated Radiation Therapy Versus Proton Therapy for Mediastinal Lymphoma. Advances in Radiation Oncology, 2020, 5, 1255-1266.	0.6	11
22	Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Network Open, 2020, 3, e2013935.	2.8	8
23	Daily computed tomography image guidance: Dosimetric advantages outweigh low-dose radiation exposure for treatment of mediastinal lymphoma. Radiotherapy and Oncology, 2020, 152, 14-18.	0.3	3
24	Genomic and Transcriptomic Characterisation of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Cancers, 2020, 12, 1808.	1.7	13
25	Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Advances, 2020, 4, 2871-2883.	2.5	134
26	The Impact of an Introductory Radiation Oncology Curriculum (IROC) for Radiation Oncology Trainees Across the United States and Canada. International Journal of Radiation Oncology Biology Physics, 2020, 107, 408-416.	0.4	13
27	Partial omission of bleomycin for earlyâ€stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?. EJHaem, 2020, 1, 272-276.	0.4	5
28	New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. Haematologica, 2020, 105, e355-e357.	1.7	10
29	Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET–CT-documented First Remission. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 533-541.	0.2	2
30	High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC). Blood, 2020, 136, 32-33.	0.6	0
31	Association of Epstein-Barr Virus with Advanced Stage and Survival Outcomes in Classic Hodgkin's Lymphoma. Blood, 2020, 136, 37-38.	0.6	0
32	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. Blood, 2020, 136, 17-18.	0.6	0
33	Association of Smoking with Advanced Stage and Survival Outcomes in Classic Hodgkin's Lymphoma. Blood, 2020, 136, 34-35.	0.6	0
34	Association of Vitamin D Deficiency with Inferior Treatment Outcomes in Patients with Newly Diagnosed Classic Hodgkin Lymphoma: MD Anderson Cancer Center Experience. Blood, 2020, 136, 27-28.	0.6	1
35	Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed after Frontline Lenalidomide and Rituximab. Blood, 2020, 136, 31-32.	0.6	2
36	Brentuximab Vedotin with Chemotherapy in Frontline Treatment of Classic Hodgkin Lymphoma Nodular Sclerosis Syncytial Variant. Blood, 2020, 136, 28-29.	0.6	0

#	Article	IF	CITATIONS
37	Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. Blood, 2020, 136, 27-28.	0.6	0
38	Real Life Treatment Alterations of Frontline Therapies in Classic Hodgkin's Lymphoma. Blood, 2020, 136, 23-24.	0.6	0
39	Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma. Leukemia and Lymphoma, 2019, 60, 3258-3265.	0.6	1
40	Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e465-e469.	0.2	7
41	Rainbow IMRT and Volumetric Imaging for Anterior Mesenteric Targets. Practical Radiation Oncology, 2019, 9, 147-152.	1.1	Ο
42	Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. International Journal of Radiation Oncology Biology Physics, 2019, 104, 447-455.	0.4	31
43	Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 381-389.	0.2	3
44	Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy. Leukemia and Lymphoma, 2019, 60, 2432-2440.	0.6	2
45	Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 244-250.	0.2	11
46	Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. Radiotherapy and Oncology, 2019, 133, 54-61.	0.3	37
47	A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma. Scientific Reports, 2019, 9, 1322.	1.6	62
48	Frontline antibiotic therapy for earlyâ€stage Helicobacter pylori â€negative gastric MALT lymphoma. American Journal of Hematology, 2019, 94, E150-E153.	2.0	7
49	Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Advances, 2019, 3, 1356-1367.	2.5	12
50	In Regard to Marcrom etÂal. International Journal of Radiation Oncology Biology Physics, 2019, 104, 220-221.	0.4	3
51	Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e51-e61.	0.2	7
52	Postâ€ <scp>ABVD</scp> biopsy results, and not postâ€ <scp>ABVD FDG</scp> â€ <scp>PET</scp> results, predict outcome in earlyâ€stage Hodgkin lymphoma: response to Adams and Kwee. British Journal of Haematology, 2019, 184, 292-293.	1.2	0
53	Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma. Blood, 2019, 134, 1609-1609.	0.6	6
54	Coronary Artery Dose-Volume Parameters Predict Risk of Calcification After Radiation Therapy. Journal of Cardiovascular Imaging, 2019, 27, 268.	0.2	30

#	Article	IF	CITATIONS
55	Maintenance Rituximab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) in the First Line Setting or at Relapse. Blood, 2019, 134, 5291-5291.	0.6	0
56	Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1146-1154.	0.4	15
57	Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. Leukemia and Lymphoma, 2018, 59, 2650-2659.	0.6	2
58	Effectiveness of definitive radiotherapy for squamous cell carcinoma of the vulva with gross inguinal lymphadenopathy. Gynecologic Oncology, 2018, 148, 474-479.	0.6	24
59	Preâ€treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. British Journal of Haematology, 2018, 180, 545-549.	1.2	38
60	Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. Leukemia and Lymphoma, 2018, 59, 2896-2903.	0.6	12
61	Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 101, 530-540.	0.4	23
62	Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood, 2018, 131, 84-94.	0.6	78
63	Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms. OncoTargets and Therapy, 2018, Volume 11, 8937-8942.	1.0	2
64	Positron emission tomography–computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Advances, 2018, 2, 1334-1343.	2.5	23
65	Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement. Case Reports in Oncology, 2018, 11, 721-728.	0.3	1
66	Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Advances in Radiation Oncology, 2018, 3, 639-646.	0.6	9
67	Simulation as More Than a Treatment-Planning Tool: A Systematic Review of the Literature on Radiation Oncology Simulation-Based Medical Education. International Journal of Radiation Oncology Biology Physics, 2018, 102, 257-283.	0.4	41
68	Introductory Radiation Oncology Curriculum: Report of a National Needs Assessment and Multi-institutional Pilot Implementation. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1029-1038.	0.4	13
69	Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. Advances in Radiation Oncology, 2017, 2, 455-464.	0.6	18
70	Multi-institutional Randomized Trial Testing the Utility of an Interactive Three-dimensional Contouring Atlas Among Radiation Oncology Residents. International Journal of Radiation Oncology Biology Physics, 2017, 98, 547-554.	0.4	31
71	Earlyâ€stage Hodgkin lymphoma outcomes after combined modality therapy according to the postâ€chemotherapy 5â€point score: can residual petâ€positive disease be cured with radiotherapy alone?. British Journal of Haematology, 2017, 179, 488-496.	1.2	9
72	Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: Effectiveness and toxicity after photon or proton treatment. Practical Radiation Oncology, 2017, 7, e401-e408.	1.1	21

#	Article	IF	CITATIONS
73	Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. International Journal of Radiation Oncology Biology Physics, 2017, 97, 333-338.	0.4	10
74	H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-β-Catenin Signaling in Colorectal Cancer. EBioMedicine, 2016, 13, 113-124.	2.7	106
75	In Regard to Ahmed etÂal. International Journal of Radiation Oncology Biology Physics, 2016, 94, 1221-1222.	0.4	2
76	Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation. International Journal of Radiation Oncology Biology Physics, 2016, 96, 110-118.	0.4	9
77	Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?. International Journal of Radiation Oncology Biology Physics, 2016, 96, 951-958.	0.4	6
78	Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma. Radiotherapy and Oncology, 2016, 121, 395-401.	0.3	210
79	A Prostate Fossa Contouring Instructional Module: Implementation and Evaluation. Journal of the American College of Radiology, 2016, 13, 835-841.e1.	0.9	10
80	Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy. Leukemia and Lymphoma, 2016, 57, 34-38.	0.6	34
81	Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PLoS ONE, 2016, 11, e0156910.	1.1	8
82	Imaging Changes in Pediatric Intracranial Ependymoma Patients Treated With Proton Beam Radiation Therapy Compared to Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, 54-63.	0.4	108
83	Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 664-670.e2.	0.2	4
84	Radiation Pneumonitis Risk after Bleomycin Toxicity in Hodgkin Lymphoma Patients. Blood, 2015, 126, 1511-1511.	0.6	0
85	The evolving evidence for the efficacy and safety of charged particle therapy for hepatocellular carcinoma-a commentary. Annals of Translational Medicine, 2015, 3, 364.	0.7	0
86	Renal lymphomatous infiltration by mantle cell lymphoma: Treatment with chemoradiation and initiation of angiotensin converting enzyme (ACE) inhibitor for renal protection. Journal of Onco-Nephrology, 0, , 239936932110398.	0.3	2